Bacteriophage Market Size, Share, Growth, And Global Industry Growth, By Type (Dsdna Bacteriophage, Ssdna Bacteriophage, Ssrna Bacteriophage, And Others), By Application (Animal Health, Aquaculture, Agriculture, Food Industry, Human Health, And Others), Covid-19 Impact, Latest Trends, Segmentation, Driving Factors, Restraining Factors, Key Industry Players, Regional Insights and Forecast From 2025 To 2033

• 

  Request a Free sample to learn more about this report

BACTERIOPHAGE MARKET REPORT OVERVIEW

The global bacteriophage market size was approximately USD 0.06 billion in 2024 and is projected to grow to USD 0.26 billion by 2033, at a CAGR of 20% during the forecast period.

Bacteriophage is a naturally occurring antibacterial agent that can be found in water, soil, sewage, and seven other areas where bacteria are present. Since the discovery of phages, several researchers have looked at their potential as medicinal agents. They are commonly utilized in food biocontrol, and lytic products are used as a natural technique. The environment was used to regulate the product description and target harmful germs.

An increase in the number of research centers is noticed with the increase in inpatient care coupled with the supplement of products. Due to these key factors, demand is expected to grow for the product. It can be used in the treatment of skin and hair-related issues. It also helps in reducing the intestinal colonization of animals that produce food. These factors are estimated to bolster the growth of the market.

COVID-19 IMPACT

Increasing R&D Activities for Vaccine Formulation to Bolster Market Progress

The global COVID-19 pandemic has been unprecedented and staggering, with the product experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The spike in CAGR is attributable to the bacteriophage market growth and demand returning to pre-pandemic levels once the pandemic is over.

The pandemic outbreak affected the market growth as it disturbed the supply chain. Prominent players operating in the global market faced major challenges due to the pandemic. The challenges involved the management of the supply chain and distribution of the product. Major disruption was noticed in the market as the pandemic caused the disturbance in clinical trial executions in the U.S., which affected the stakeholders across the world. 

Furthermore, over the past few decades, diagnosis of diseases such as HIV, tuberculosis, and malaria have concluded that without effective preventative treatments, vaccinations or resolution, the pandemic will gradually require an approach with multi-facets. Various diseases, such as influenza, made an impression that vaccines have proven to be highly effective at limiting and controlling the virus spread. Many aspects are there in drug development to find leads. This editorial focuses on the potential of bacterial phages that may be useful in controlling the COVID-19 pandemic.

LATEST TRENDS

Government Funding to Support R&D Activities to Propel Market Growth

The bacteriophage market is anticipated to grow substantially due to the increasing incidence of resilient antibiotic infection, growing R&D activities to improve novel therapies, increasing adoption of growth strategies such as mergers & acquisitions, and collaborations by prominent players. Moreover, high investment by the government is expected to treat infections caused by antibiotic-resistant bacteria, propelling the bacteriophage market growth. Moreover, the increase in research activities for the development of therapy, rising adoption of growth strategies, and manufacturing of antibiotic-resistant infections are anticipated to spur growth in the market. For instance, in 2019, BiomX Ltd, an Israel-based phage therapy firm, merged with New York-listed Chardan Healthcare Acquisition Corp. (CHAC). The company, after a merger, is led by BiomX ltd.

• Rising antimicrobial resistance (AMR): According to the World Health Organization (WHO), antimicrobial resistance can cause 10 million deaths annually by 2050. If the current trend continues, the disasters bacteriocf that is urgent for alternative agents such as therapy. 
• Progress in phase therapy research: In Australia, stamp studies have treated around 30 patients since April 2022, who focus on standardizing the phase therapy administration and monitoring patients. 
• Extension of global clinical studies: More than 90 clinical studies are ongoing worldwide, reflecting a global commitment to the discovery of phase -based solutions, and assesses bacteriocf treatment for conditions such as chronic urinary tract infections and cystic fibrosis.

Request a Free sample to learn more about this report

BACTERIOPHAGE MARKET SEGMENTATION

By Type

By type, the phage therapy market is segmented into dsDNA Bacterial phage, ssDNA Bacteriophage, SsRNA phage therapy, and others.

By Application 

Based on application, the market is classified into animal health, aquaculture, agriculture, food industry, human health, and Others.

The food industry is expected to occupy the largest revenue contribution in the global bacteriophage market share. They are widely used in the industry to save food from pathogenic bacteria. Wide applications in the food industry are likely to boost demand for products. Escalated use of therapy in various applications, such as discovering and developing drugs, is estimated to provide fat growth to this segment.

MARKET DYNAMICS

DRIVING FACTORS

Increased Antibiotic-Resistant Production to Bolster Growth

The market is anticipated to grow rapidly due to the consistently rising production of antibiotic-resistant infections. The research activities for the therapy development are expected to support the adoption of growth strategies. The demand for the product is expected to boom due to its wide applications. To meet the customer's demand, the production of antibiotic-resistant products is expected to bolster the market. Additionally, the government funding is also expected to assist the market manufacturers in developing a novel approach to reduce the cases of antimicrobial-resistant infection. Moreover, increased government funding to assist bacteriophage market manufacturers in developing a novel approach to reduce the cases of antimicrobial-resistant infection is expected to boost the market growth.

• Prevalence of Antibiotic-Resistant Infections: The Centers for Disease Control and Prevention (CDC) estimates that at least 2.8 million infections arise each year inside the U.S. Due to antibiotic-resistant micro organism, highlighting the need for alternative treatments like bacteriophage therapy. ​
• Investment in Biotechnology: Asia Pacific is the quickest-growing location within the bacteriophage marketplace, pushed by growing investments in biotechnology and a growing call for for bacteriophage therapy. ​

RESTRAINING FACTORS

Availability of Alternative Drugs to Hinder Market Growth 

The availability of alternative drug treatments for antimicrobial-resistant infections may impede the growth of the therapy market during the forecast period. For example, The Food and Drug Administration approved Pretomanid Tablets in combination with Bedaquiline and Linezolid in August 2019 to treat a specific type of highly treatable tuberculosis (TB) of the lungs. 

• Regulatory Challenges: In areas like the U.S. And EU, bacteriophage therapy plans are nevertheless considered experimental, with get entry to regularly limited to compassionate use frameworks, hindering tremendous adoption. ​
• Limited Awareness and Standardization: The lack of standardized protocols and limited recognition among healthcare specialists make a contribution to inconsistent utility and skepticism regarding bacteriophage therapy. ​

• Request a Free sample to learn more about this report

•  

BACTERIOPHAGE MARKET REGIONAL INSIGHTS

Technological Advancement to Strengthen Market Position in North America

North America is forecasted to dominate the global market, backed by steady recovery and therapeutic effects offered by lytic phage therapy. Georgia is expected to surge the regional growth due to the adoption of new advancements in phage therapy. 

Asia Pacific is forecasted to be the second dominating region in the global market share. The region's growth is attributed to the ever-expanding investment in innovation and research and development for drug products. China is expected to be the major cause of the region’s growth as it is anticipated to invest more in product development. 

Competitive Landscape

Steady Adoption of Inorganic Growth Strategies to Enhance Market Position

The bacterial phage market share is expected to boom rapidly due to the steady adoption of inorganic growth strategies such as collaborations, facility expansion, and acquisitions. These strategies are expected to enhance the presence of key players in the potential market, which would surge growth in the near future. Market participants are increasingly focusing on inorganic growth strategies such as collaborations and partnerships to strengthen their pipeline of phage therapy candidates and to improve their research and development capabilities.

List Of Top Bacteriophage Companies

• NPO Microgen (Russia)
• Proteon Pharmaceuticals (Poland)
• Phagelux (China)
• Intralytix (U.S.)
• Micreos (Netherlands)
• Eliava BioPreparations (Georgia)
• Locus Biosciences, Inc (U.S.)
• Pharmex Group, LLC (Ukraine)
• Pherecydes Pharma (France)
• APS Biocontrol Ltd. (APS) (U.K.)
• Qingdao Phagepharm Bio-tech (China)
• Fixed-Phage Limited (U.K.)
• Zeptometrix (New York)
• Phage International, Inc. (U.S.)
• MicroMir (India)
• iNtODEWORLD, Inc. (U.S.)
• NEXTBIOTICS (U.S.)
• Armata Pharmaceuticals, Inc. (U.S.)
• Innophage (Portugal)

INDUSTRY DEVELOPMENT

• April 2020- Phagelux, Inc. unveiled its entrance into various commercial collaborations such as marketing, European sales, and the product development with DCM. This collaboration was made for the company’s AgriPhage line of biopesticides. This collaboration encouraged the company to explore and develop next-generation phage therapy. 
• NPO Microgen: As of 2024, NPO Microgen operates nine manufacturing web sites throughout Russia, producing over 250 medical products, consisting of bacteriophages, and employs about five,500 experts. ​
• Proteon Pharmaceuticals: In September 2023, Proteon Pharmaceuticals inaugurated the Center for Bacteriophage Biotechnology (CBB) to increase studies in bacteriophage formulations, specializing in improving delivery strategies, stability, and shelf lifestyles of phage products.

REPORT COVERAGE

The report offers an elaborative report on the major factors driving market growth and the trends responsible for surging maximum growth in the market. The region’s leading the global market are depicted to offer insights into the regional markets. Moreover, recent industry developments and the strategies adopted by the key players are included. The impacts of the pandemic and how it has affected market growth are also represented in the report. Segmentation of the market based on its attributes offers detailed information about the market. Additionally, the segment dominating the market and is expected to boost growth is also covered.